From: Quercetin and polycystic ovary syndrome, current evidence and future directions: a systematic review
Type of study | Authors/date | Source | Model | Results |
---|---|---|---|---|
Animal | Wang et al. 2017 [30] | China | 132 female Wistar rats (21 days old)/IR PCOS rat model/2 mL of quercetin solution (100 mg/kg)/ for 28 days | Quercetin treatment in the insulin-resistant PCOS rat model led to: |
- 58.33% recovery rate of the estrous cycle, significant reduced the levels of blood insulin, interleukin 1β, IL-6, and tumor necrosis factor α. | ||||
- Significant decreased the granulosa cell nuclear translocation of NF-κB | ||||
- Inhibited the expression of inflammation-related genes, including the nicotinamide adenine dinucleotide phosphate oxidase subunit p22phox, oxidized low-density lipoprotein, and Toll-like receptor 4, in ovarian tissue. | ||||
- IR improvement | ||||
Jahan et al. 2018 [31] | Pakistan | Twenty-four adult female Sprague Dawley rats (60–70 days old and 180 ± 10 g body weight; randomly divided into four groups (n = 6–8))/quercetin (30 mg/kg) for 21 days. | By Quercetin administration: | |
- No difference in mean body weight | ||||
-Restoration of the estrous cycle | ||||
-Significant decrease in ovarian diameter and in cystic follicle diameter | ||||
-Number of ovarian follicles were declined as compared to untreated PCOS group | ||||
-Counterbalanced the ROS levels and improved the antioxidant activities | ||||
- Optimized the values of progesterone, estradiol, and testosterone levels when compared to control | ||||
-Improvement of lipid profile (decreased cholesterol and triglyceride levels) and glucose levels. | ||||
Neisy et al. 2018 [32] | Iran | Thirty-five Sprague–Dawley female rats (DHEA-induced PCOS) randomly divided into five groups: (1) Control group, didn’t receive any treatment for 30 days; (2) quercetin (Q) group, treated with quercetin gavage (15 mg kg−1quercetin (3) ethanol vehicle group (ethanol gavage) for 30 days; (4) PCOS group (5) PCOSQ group (induced PCOS and then were treated with 15 mg kg− 1 quercetin for 30 days). 15 mg kg_1 quercetin for 30 days | Quercetin significantly: | |
-Improved folliculogenesis and luteinisation | ||||
-Improved IR and decreased insulin levels | ||||
-Increased activities of liver GK and HK | ||||
↑ Expression of uterine GLUT4 and ERa genes | ||||
Shah et al. 2016 [33] | India | Forty-eight Sprague–Dawley female rats (3-week-old)/Quercetin (150 mg/kg, p.o.)/4 week. | Quercetin led to: | |
- ↓ CYP17A1 gene expression | ||||
- PI3 kinase inhibition | ||||
-Decreased testosterone and LH levels | ||||
-Significant improvement in insulin, testosterone, LH, and lipid profile (decreased HDL level was improved and significant reduction in serum cholesterol, triglyceride, LDL, and VLDL levels) | ||||
-Significant improvement in the uterus histology | ||||
-Improvement in cyst formation, folliculogenesis, and luteinisation | ||||
- Did not modify body weight gain | ||||
Hong et al. 2018 [34] | China | Sprague–Dawley female rats. (25 mg Quercetin /kg body weight for 4 week. | Quercetin led to: | |
-Reversed the PCOS ovarian morphology. | ||||
-↑ The levels and activities of antioxidant enzymes: CAT, SOD and GPX | ||||
-Prevented weight gain | ||||
-Caused significant decline in serum glucose | ||||
-Normalized estradiol, testosterone levels, and steroidogenic enzyme activities in PCOS subjects | ||||
-Blocked PCOS-related abnormalities and exerted protective effects on the ovary anatomy. | ||||
Human | Rezvan et al. 2017 [35] | Iran | 84 women with PCOS (20–40 years old; and had the BMI of 25–40 kg/m2) randomly assigned to 2 groups. The treatment group received 1 g quercetin (two 500 mg capsules (Jarrow, USA) after each main meal (breakfast and lunch) for 12 weeks. The control group received placebo(2 capsules containing starch for 12 weeks) | Quercetin led to: |
-Increased the level of adiponectin by 5.56% and HMW adiponectin by 3.9% reduced the level of testosterone, LH, and HOMA-IR levels were also significantly reduced in quercetin group reduced of FBS, and insulin levels without changing BMI and WHR | ||||
-Oral quercetin supplementation was effective in improving the adiponectin-mediated insulin resistance and hormonal profile of women with PCOS. | ||||
Khorshidi et al. 2018 [36] | Iran | 78 overweight or obese women (25 ≤ BMI ≤ 40 kg/m2, 20–40 years) with PCOS 1000 mg/day quercetin or placebo for 12 weeks | Quercetin led to: | |
Decreased resistin plasma levels and gene expression, and testosterone and LH concentration | ||||
No significant difference in SHBG levels | ||||
FBG, fasting insulin, and insulin resistance were improved significantly in the quercetin group, but the changes were not statistically different compared with the placebo group | ||||
Rezvan et al. 2018 [37] | Iran | 84 overweight or obese women with PCOS/1 g quercetin (two 500 mg capsules) daily for 12 weeks | Quercetin: | |
Increased Adiponectin Receptors (ADIPOR1 and ADIPOR2) transcript expression by 1.32- and 1.46-fold respectively, | ||||
Enhanced AMPK level by 12.3% |